Package Leaflet: Information for the Patient
TRISENOX 1mg/ml concentrate for solution for infusion
arsenic trioxide
Read all of this leaflet carefully before you are given this medicine because it contains important information for you.
Contents of the pack
TRISENOX is used in adult patients with low to intermediate risk acute promyelocytic leukaemia (APL) who have just been diagnosed, and in adult patients whose disease has not responded to other treatments. APL is a unique type of myeloid leukaemia, a disease that produces abnormal white blood cells, bleeding, and bruising.
TRISENOX should be given under the supervision of a doctor who is experienced in the treatment of acute leukaemias.
You should not be given TRISENOX
If you are allergic to arsenic trioxide or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
You should tell your doctor or nurse before you are given TRISENOX, if:
Your doctor will take the following precautions:
Children and adolescents
TRISENOX is not recommended for children and adolescents under 18 years.
Other medicines and TRISENOX
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines, including those obtained without a prescription.
In particular, tell your doctor:
The effect of these medicines on your heart rhythm may be worsened by TRISENOX. You must make sure that you tell your doctor about all the medicines you are taking.
Using TRISENOX with food and drink
There are no restrictions on food or drink while you are being treated with TRISENOX.
Pregnancy
Ask your doctor or pharmacist for advice before taking any medicine.
TRISENOX may harm your unborn baby if you are given it while you are pregnant.
If you can become pregnant, you should use effective contraception during treatment with TRISENOX.
If you are pregnant or become pregnant during treatment with TRISENOX, tell your doctor.
Men should use effective contraception during treatment with TRISENOX.
Breast-feeding
Ask your doctor or pharmacist for advice before taking any medicine.
Arsenic from TRISENOX passes into breast milk.
As TRISENOX may harm your baby, you should avoid breast-feeding while you are being treated with TRISENOX.
Driving and using machines
TRISENOX is unlikely to affect your ability to drive or use machines.
If you feel unwell or experience side effects after an injection of TRISENOX, you should wait until these effects have gone away before driving or using machines.
TRISENOX contains sodium
TRISENOX contains less than 1 mmol of sodium (23 mg) per dose. This means that the medicine is essentially "sodium-free".
Duration and frequency of treatment
Patient with newly diagnosed acute promyelocytic leukaemia
Your doctor will give you TRISENOX once a day by infusion. In the first treatment cycle, you may receive treatment every day for up to 60 days, or until your doctor decides that your disease has improved. If your disease responds to TRISENOX, you will receive 4 additional treatment cycles. Each cycle consists of 20 doses, given 5 days a week (followed by 2 days off) for 4 weeks (followed by a 4-week break). Your doctor will decide exactly how long you should continue treatment with TRISENOX.
Patient with acute promyelocytic leukaemia whose disease has not responded to other treatments
Your doctor will give you TRISENOX once a day by infusion. In your first treatment cycle, you may receive treatment every day for up to 50 days, or until your doctor decides that your disease has improved. If your disease responds to TRISENOX, you will receive a second treatment cycle of 25 doses, given 5 days a week (followed by 2 days off) for 5 weeks. Your doctor will decide exactly how long you should continue treatment with TRISENOX.
Form and route of administration
TRISENOX must be diluted with a solution containing glucose or a solution containing sodium chloride.
TRISENOX is usually given by a doctor or nurse. It is given through a drip (infusion) into a vein over 1-2 hours, but the infusion may take longer if you experience side effects such as flushing and dizziness.
TRISENOX must not be mixed or injected with other medicines through the same tube.
If your doctor or nurse gives you more TRISENOX than you should have
You may experience seizures, muscle weakness, and confusion. If this happens, treatment with TRISENOX should be stopped immediately and your doctor will treat the arsenic overdose.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or nurse immediately if you notice any of the following side effects, as they could be signs of a serious condition called "differentiation syndrome", which can be life-threatening:
Tell your doctor or nurse immediately if you notice any of the following side effects, as they could be signs of an allergic reaction:
While you are being treated with TRISENOX, you may experience some of the following reactions:
Very common side effects (may affect more than 1 in 10 people):
Common side effects (may affect up to 1 in 10 people):
Frequency not known (cannot be estimated from the available data):
Reporting of side effects
If you experience any side effects, talk to your doctor, pharmacist, or nurse, even if they are not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the ampoule label and carton.
No special storage conditions are required.
After dilution, if not used immediately, the storage conditions and storage time before use are the responsibility of the user and are normally not more than 24 hours at 2-8°C, unless the dilution has been carried out under aseptic conditions.
Do not use this medicine if you notice any visible signs of deterioration or if the solution is discoloured.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
What TRISENOX contains
Appearance and pack contents
TRISENOX is a concentrate for solution for infusion (sterile concentrate). TRISENOX is supplied in glass ampoules as a clear, colourless, aqueous solution. Each carton contains 10 glass ampoules for single use.
Marketing authorisation holder
Teva B.V., Swensweg 5, 2031 GA Haarlem, Netherlands
Manufacturer
Almac Pharma Services Limited, Almac House, 20 Seagoe Industrial Estate, Craigavon, BT63 5QD, UK
Almac Pharma Services (Ireland) Limited; Finnabair Industrial Estate, Dundalk, Co. Louth, A91 P9KD, Ireland
Teva Pharmaceuticals Europe B.V., Swensweg 5, 2031 GA Haarlem, Netherlands
Date of last revision of this leaflet: {MM/YYYY}
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu
There are also links to other web sites about rare diseases and orphan medicines.
------------------------------------------------------------------------------------------------------------------
This information is intended only for healthcare professionals:
STRICT ASEPTIC TECHNIQUE SHOULD BE FOLLOWED DURING THE HANDLING OF TRISENOX AS IT DOES NOT CONTAIN PRESERVATIVES.
Dilution of TRISENOX
TRISENOX must be diluted before administration.
Staff should be properly trained to handle and dilute arsenic trioxide and should wear adequate protective equipment.
Opening the ampoule: Hold the TRISENOX ampoule with the coloured tip facing upwards and away from you. Shake it gently or tap it to ensure that any liquid in the neck of the ampoule is returned to the body of the ampoule. Now press the coloured tip with your thumb and break the ampoule while firmly holding the body of the ampoule with your other hand.
Dilution: Carefully insert the needle of a syringe into the ampoule and withdraw all of the contents.
TRISENOX should be diluted immediately after opening with 100 to 250 ml of injectable glucose 50 mg/ml (5%) or injectable sodium chloride 9 mg/ml (0.9%) solution.
Unused portions of each ampoule should be discarded in a suitable manner. Do not store any unused portion for later administration.
Use of TRISENOX
TRISENOX is for single use. It must not be mixed or administered with other medicines through the same intravenous line.
TRISENOX will be injected into a vein over 1-2 hours, but the infusion time may be extended up to 4 hours if vasomotor reactions are observed. A central venous catheter is not required.
The diluted solution should be clear and colourless. Before administration, all parenteral solutions should be inspected visually for particulate matter and discolouration. Do not use the preparation if there are signs of particles.
After dilution in intravenous solutions, TRISENOX is chemically and physically stable for 24 hours at 15-30°C and for 72 hours refrigerated (2-8°C). From a microbiological point of view, the product should be used immediately. If not used immediately, the storage conditions and storage time before use are the responsibility of the user and are normally not more than 24 hours at 2-8°C, unless the dilution has been carried out under validated aseptic conditions.
Procedure for proper disposal
Disposal of unused medicine and all materials that have been in contact with it should be done in accordance with local regulations.